Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Information Regarding Use of Monoclonal Antibodies for Treatment or Prevention of COVID-19 October 01, 2021 Ancillary COVID-19 Pharmacy

As COVID-19 cases rise in North Carolina, monoclonal antibodies remain an important tool to help slow the progression of the virus in our communities and reduce the overall strain on the healthcare system. 

The Food and Drug Administration has issued an Emergency Use Authorization to allow the use of monoclonal antibody therapies for the treatment of mild to moderate COVID-19 in certain high-risk patients. Additionally, the FDA authorized this treatment for use in some patients who are exposed to COVID-19 even if they do not have symptoms. People who are not fully vaccinated or who have immunocompromising conditions, including those taking immunosuppressive medications, and have either been exposed to COVID-19 or are at high risk of exposure due to where they live or work may qualify for preventative treatment.

Monoclonal antibody therapy must be administered within 10 days of the start of COVID-19 symptoms, so early testing is crucial. 

While authorized for emergency use since last November, there have been some recent changes related to monoclonal antibodies that have significantly increased the manageability and ease of administering these products:

  • The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel gives monoclonal antibodies an “AIIa” rating, strongly recommending the use of these products to treat outpatients with mild to moderate COVID-19 who are at high-risk of clinical progression.
  • The patient eligibility criteria for monoclonal antibodies were recently expanded, giving providers more freedom to use their clinical judgement in determining who meets the emergency use authorization (EUA) definition of being at high-risk for progression to severe COVID-19.
  • REGEN-COVTM (casirivimab and imdevimab) is now authorized to be administered via subcutaneous injection and in some cases can be used as post-exposure prophylaxis in high-risk patients who have been exposed to someone with COVID-19.

Additional resources

  • See Monoclonal Antibody info, including how to order direct from USDHHS
  • Monoclonal antibodies remain available at no cost from the federal government.  Interested providers, capable of adhering to the EUA requirements, can request product directly from AmerisourceBergen.
  • Providers currently offering monoclonal antibodies in NC can be found using this COVID-19 Antibody Therapy Locator from the National Infusion Center Association (NICA).
  • Provider FAQs.